summari report sale
ex-fx organ came
consensu estim
non-gaap ep ex-fx exceed our/consensu
estim guidanc provid revenu
guidanc organ growth impli sale growth
growth guidanc previous
provid rais ep guidanc
previous midpoint overal
certainli view quarter disappoint manag
remain commit acceler top-lin
view achiev given steadi cadenc upcom
product launch healthi pipelin
chang estim lower sale estim
organ lower sale
estim organ non-gaap
ep rais estim
report rais estim
 recap sale came
consensu estim
mdt organ growth also fell short guidanc
attribut top-lin miss primarili reduct
custom order anticip new product launch cvg
rtg erp upgrad mitg provid disrupt us
ep ex-fx came ahead
consensu estim attribut beat
better-than-expect foreign exchang
upsid vs model mostli due higher gross margin
vs estim slightli lower oper expens
vs estim lower net interest expens
vs estim lower tax rate vs
estim
continu follow page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
ep exclud amort reflect combin follow
acquisit cov
compani data secur llc estim reuter
continu previou page
revenu segment mostli miss cardiac vascular group sale
ex-fx consensu estim cardiac rhythm heart failur sale
ex-fx roughli in-lin consensu estim coronari
structur heart sale ex-fx came consensu
estim aortic peripher revenu ex-fx
in-lin
estimate/consensu minim invas therapi group revenu grew ex-fx vs
consensu forecast restor therapi group sale rose ex-fx
miss consensus/our forecast diabet revenu ex-fx
growth exceed consensu forecast
crhf perform stabil though continu headwind icd heart failur crhf
cardiac rhythm heart failur sale grew improv sequenti
reflect low-singl digit growth arrhythmia manag low-singl digit declin
heart failur hf within pacemak grew high-singl digit given strong micra growth
us icd declin high-singl digit given replac cycl headwind ramp tyrx
manufactur chang last quarter custom wait cobalt/chrom high power devic
launch month europ expect launch us addit af atrial
fibril solut grew high singl digit vs low singl digit continu uptak
arcticfront cryoballoon diagnost dx sale grew mid-singl digit vs low-singl digit growth
driven reveal linq continu adopt off-set custom wait linq approv
continu soft hf reflect on-going headwind crt-d cardiac resynchron therapi
defibril replac cycl lvad appear stabil quarter growth headwind
mdt lvad busi includ competit abt dt destin therapi
us approv chang us guidelin depriorit heart transplant
patient lvad bridge-to-transpl popul lvad perform stabil
quarter sale declin low-singl digit ww us vs sale declin high
ww us importantli lap step lvad
ex-fx compar csh growth larg driven
transcathet aortic valv replac tavr growth mid-teen ww us
growth compar ew ww tavr growth oper ex-fx includ
growth ou growth estim believ possibl disconnect
ew strong result mdt soft result demonstr low risk data ew reson
market recal ew studi demonstr superior wherea mdt low risk trial
howev believ growth market due new sale forc hire us
ramp quickli expect sale rep focus launch evolut pro devic
addit ramp new center expect come on-line result june ncd nation
coverag decis go forward plan hire increment sale rep support staff
bolster growth anticip refocu back larg account addit messag
improv hemodynam benefit evolut pro separ de drug elut stent declin low-
singl digit world-wide includ mid-singl digit declin us low-singl digit declin ou
apv growth improv dcb headwind start eas apv aortic peripher
vascular sale grew ex-fx slightli better growth deceler
mid-singl digit growth dcb drug coat balloon remain growth headwind
sale fall ww us encouragingli us dcb sale grew sequenti
second consecut quarter manag believ sequenti growth trend could continu
futur dcb data analysi remain rel posit expect next key dcb data
present american colleg cardiolog meet focu claims-bas
analysi estim competitor bdx lutonix yr/yr sale declin also eas somewhat recent
compar declin prior coupl quarter estim
lutonix sale like also improv bit sequenti mdt offset dcb sale declin
high-singl digit growth taa thorac aortic aneurysm deceler high-teen growth due
tough comp growth venou mid-singl digit rel stabl compar
venas closur continu strong uptak
neurovascular neurosurgeri continu lead growth brain therapi brain therapi
sale grew slightli low-doubl digit growth perform led mid-
teen growth neurovascular larg consist continu low-doubl digit growth
neurosurgeri within neurovascular report growth ischem stroke mid-
teen growth flow divers specif ischem stroke cite strong adopt new
solitair stent retriev riptid aspir system react aspir cathet ischem stroke sale
grew high-teen us ou repres slight deceler mid-teen
respect neurosurgeri compani point continu healthi capit
equip sale includ strong mazor stealth believ mazor unit volum sale
continu outpac competit
neurovascular market growth appear stabl seem outperform ischem
stroke mdt neurovascular busi grew mid-teen high-teen last quarter
compar syk ex-fx growth neurotech competitor report
result feb face tough yr/yr comparison combin basi estim
neurovascular sale grew ex-fx slightli growth stack
basi growth fairli stabl market base result region estim
approxim mid-teen growth us vs high-teen growth ou togeth
ischem stroke sale grew ww high-teen us growth ou
reflect strong adopt solitair riptid react
spine growth deceler global spine sale y/i organ
deceler versu y/i organ level y/i organ
sequenti quarter repres tough comparison mdt spine franchis deliv highest organ
growth quarter ten quarter aid one-tim distributor start-up order bmp bone
morphogenet protein note result adjust titan spine acquisit
contribut report sale quarter divis spine perform stack
follow core spine portfolio repres two-third mdt total spine sale deliv
organ growth low-singl digit slightli level manag
call notabl chang underli market dynam result continu
driven robot pull-through new product penetr stratospher infin oct
prestig lp cervic disc system bmp busi repres total sale deliv
high-singl digit sale declin driven custom buy pattern revers versu
low doubl digit growth due one-tim initi distributor start-up order place
sequenti quarter core spine busi combin enabl technolog report
neurosurgeri brain therapi deliv organ growth y/i global
repres deceler versu ww includ
compar level ww includ look ahead surgic synergi
strategi remain key focu manag expect trend posit go forward
help drive adopt capit implant ahead competit
pain franchis sale growth deceler global pain therapi sale
repres constant currenc organ growth y/i level y/i
level y/i result reflect low doubl digit growth emerg market
off-set declin non-u develop market manag note
spinal cord stimul market continu slow compani lost share
last earn call manag note expect market flattish least next two
quarter trace back mid-to-high singl digit growth rang thereaft driven new product
posit trial growth estim mdt ww sale total
ex-fx includ sale us use mdt result estim
global market declin y/i ex-fx improv estim declin
declin estim us market declin
versu within mdt portfolio intelli sale grew nice manag expect
acceler launch quarter ahead like continu off-set declin primari
cell busi final launch dtm differenti target multiplex waveform nan north
american neuromodul societi januari initi dtm indic expans trial upper
limb pre-op spine
mitg perform depress erp upgrad acceler expect mitg sale
total ex-fx growth compani guidanc due erp system
upgrad us canada late quarter erp implement face suppli
constraint result lost procedur mitg growth also lag growth
manag report system upgrad complet product suppli
return normal compani anticip mitg ex-fx sale growth acceler
strength advanc surgic continu drive mitg growth si surgic innov sale
grew ex-fx reflect mid-singl digit growth advanc surgic partli off-set flattish
perform gener surgic within advanc surgic advanc energi ae led way
strong high-singl digit ex-fx sale growth acceler strong mid-singl digit growth
attribut strong perform new product includ ligasur franchis
valleylab energi platform mdt ae busi outperform grew due
continu soft us mdt us ae revenu grew low-doubl digit compar jnj low-
singl digit declin us ae sale mdt advanc stapl sale grew low-singl digit led
endo gia platform tri-stapl technolog similar jnj endocutt sale growth
saw mid-singl digit declin us high-singl digit growth ou
busi gener surgeri mdt sale flattish reflect low-singl digit declin us
off-set low-singl digit increas ou jnj gener surgeri busi also flattish tougher
yr/yr comp similarli us declin off-set ou growth sutur cite mid-singl digit
growth report growth respiratori gastrointestin renal sale
grew ex-fx led growth acceler gi solut low-doubl digit growth vs high-
singl digit growth continu strength patient monitor mid-singl digit growth
remain commit execut commit robot assist surgeri
ra platform remain commit execut ra strategi laid detail
investor updat septemb recal januari push timelin initi
launch hugo surgic robot april juli due
slippag software-rel timelin mdt decis move earli procedur coupl
month addit chang state timelin maintain submiss timelin
ce mark may-juli may-octob
allow begin place system initi train gather import clinic data expect ce mark
novemb fda clearanc sometim late remind
expect growth contribut ra platform mitg
also expect platform provid robot capabl per-procedur
cost equival laparoscopi note acquir digit surgeri februari
advanc capabl artifici intellig ai well data analyt plan showcas
sage societi american gastrointestin endoscop surgeon medic meet april
diabet growth deceler sequenti due competit dynam
global diabet sale y/i ex-fx repres deceler versu
fyq level primarili due competit dynam
await launch new product off-set mid- high-teen growth outsid ou
compani sale continu deceler sequenti y/i versu
y/i y/i level make half mdt diabet sale
mix grew robust y/i pace ex-fx versu high-teen growth deliv
worth note gener global diabet sale cgm
continu glucos monitor continu see strength integr cgm stand-
alon cgm categori strength integr cgm driven increas penetr new
patient acquisit stand-alon cgm led guardian connect smart cgm system latter
grew robust pace y/i level y/i
gener global diabet sale insulin pump perform driven
on-going launch minim system intern market see strong enrol
pathway program allow buyer upgrad mdt next-gener pump
technolog upon launch compani defer portion pump sale patient trade-
current gener pump overal expect deliv low-singl digit growth
diabet busi expect growth flat slightli due
competit dynam pipelin front expect file minim clinic data fda
march push expect approv beyond also make progress
pivot trial next-gener icgm sensor provid updat next earn call
may
post anoth quarter double-digit em growth emerg market em revenu
y/i ex-fx compar manag note strong em growth
across geographi region eastern europ grew fastest follow china
southeast asia south asia middl east africa latin america
grew overal em revenu account revenu
ahead estim large-cap med-tech median em exposur
guidanc in-lin street plan provid color coronaviru impact
guid roughli top-lin organ growth exclud impact corona viru in-lin
consensu note comfort street expect segment expect
ex-fx growth cvg ex-fx growth mitg organ growth rtg
flat low-singl digit ex-fx declin diabet expect currenc headwind
sale move expect gross margin improv slightli vs sg
expens flat y/i sale expens level sale expect
oper margin flat exclud currenc would small tailwind guidanc
includ interest expens nomin tax rate approxim taken
togeth manag guid adjust ep includ fx headwind
addit manag note comfort prior consensu ep high-
end guidanc rang importantli guidanc provid tuesday call exclud
impact coronaviru term impact plan provid color quarter progress
note product facil china on-line impact would primarili driven delay
procedur current around total sale china
impli guidanc slightli prior expect math new impli
top-lin organ guidanc growth compar prior expect
growth impli guid segment follow cvg growth vs prior
diabet growth vs prior low-singl digit growth tax rate
expect year vs prior expect new ep guidanc
vs prior expect look manag said top-
line organ growth acceler currenc manag note fx expect
bigger headwind compar current rate
larg cap med-tech organ growth remain robust report tuesday
morn growth rate larg cap med-tech name use
consensu snn estim alc analysi indic world-wide organ ex-fx
sale growth y/i compar see figur
look organ growth full-year basi growth acceler cy
cy
organ growthci med-tech pf cfn average excl non-calendar year-endnot organ growth adjust currenc acquisit divestitur sell day meaning compani report secur llc estim medic technolog
price target nc
price target base cash ep estim risk
includ weak key end market greater share loss model delay product
believ acceler growth stori trade discount peer organ growth
acceler come quarter due new product launch micra av surgic
robot linq diabet pump next gener interstim renal denerv
found minneapolis-bas lead global medic technolog compani
focus provid therapi chronic diseas compani four primari busi cardiac
vascular restor therapi minim invas therapi diabet revenu
organ growth year stack med-tech pf cfn average excl non-calendar year-endnot organ growth adjust currenc acquisit divestitur sell day meaning compani report secur llc estim plc
